As the products are derived from patients with diffuse large B-cell lymphoma, we focused on the redundancy between GZMB and GZMA. We subset the infusion products based on CD4/CD8 expression and show that Axi-cel products (7–76%, 15–95%) have a higher frequency of CD8 T cells compared to Tisa-cel products (2–20%) (Fig. 8B, H, N). Here, CD8A is linked to diffuse large B-cell lymphoma.